Compare · BDX vs OSRH
BDX vs OSRH
Side-by-side comparison of Becton Dickinson and Company (BDX) and OSR Holdings Inc. (OSRH): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both BDX and OSRH operate in Medical/Dental Instruments (Health Care), so they compete in similar markets.
- BDX is the larger of the two at $52.78B, about 12899.9x OSRH ($4.1M).
- BDX has been more active in the news (9 items in the past 4 weeks vs 2 for OSRH).
- BDX has more recent analyst coverage (25 ratings vs 0 for OSRH).
- Company
- Becton Dickinson and Company
- OSR Holdings Inc.
- Price
- -
- -
- Market cap
- $52.78B
- $4.1M
- 1M return
- -
- +0.00%
- 1Y return
- -
- -79.90%
- Industry
- Medical/Dental Instruments
- Medical/Dental Instruments
- Exchange
- NYSE
- NASDAQ
- IPO
- 2023
- News (4w)
- 9
- 2
- Recent ratings
- 25
- 0
Becton Dickinson and Company
Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products worldwide. The company's BD Medical segment offers peripheral intravenous (IV) and advanced peripheral catheters, central lines, acute dialysis catheters, vascular care and preparation products, needle-free IV connectors and extensions sets, closed-system drug transfer devices, hazardous drug detection, hypodermic syringes and needles, anesthesia needles and trays, enteral syringes, sharps disposal systems; infusion pumps, dedicated disposables, IV fluids, medication compounding workflow systems, automated medication dispensing, automated supply management systems, medication inventory optimization and tracking systems; syringes, pen needles, and other products for diabetes care; and prefillable drug delivery systems. Its BD Life Sciences segment provides specimen and blood collection products and systems; automated blood and tuberculosis culturing, molecular testing, microorganism identification and drug susceptibility, and liquid-based cytology systems, as well as rapid diagnostic assays, microbiology laboratory automation products, and plated media products; and fluorescence-activated cell sorters and analyzers, antibodies and kits, reagent systems, and solutions for high-throughput single-cell gene expression analysis, as well as clinical oncology, immunological, and transplantation diagnostic/monitoring reagents and analyzers. The company's BD Interventional segment offers hernia and soft tissue repair, biological and bioresorbable grafts, biosurgery, and other surgical products; surgical infection prevention, surgical and laparoscopic instrumentation products; peripheral intervention products; and urology and critical care products. Becton, Dickinson and Company was founded in 1897 and is based in Franklin Lakes, New Jersey.
Latest BDX
- BD to Announce Financial Results for its Fourth Quarter and Full Year of Fiscal 2026
- BD and Global Health Leaders Call for Accelerated Maternal Life Saving Measures Worldwide
- BD Strengthens Leadership in Peripheral Vascular Innovation with Positive AGILITY Trial Results
- BD Celebrates 65 Years of Manufacturing, Innovation and Community Partnership in Canaan
- BD Appoints Ferass Abuzaina as Worldwide President of Surgery
- BD and U.S. Government Launch Landmark Partnership to Expand U.S. Manufacturing and Strengthen America's Healthcare Resilience
- EVP, Chief Revenue Officer Feld Michael sold $13,961 worth of shares (76 units at $183.70) as part of a pre-agreed trading plan, decreasing direct ownership by 0.39% to 19,644 units (SEC Form 4)
- BD Celebrates 70 Years of Manufacturing, Innovation and Community Partnership in Sandy
- Arthur Hu to Join BD as Chief Information and Digital Officer
- BD Advances Intelligent Robotics to Transform the Future of Pharmacy Care at Fairview
Latest OSRH
- SEC Form 8-K filed by OSR Holdings Inc.
- OSR Holdings Inc. filed SEC Form 8-K: Leadership Update
- OSR Holdings Inc. filed SEC Form 8-K: Other Events
- Emerging Growth Research Issues Company-Sponsored Research Flash Report on OSR Health, Inc.
- OSR Holdings Inc. filed SEC Form 8-K: Other Events
- OSR Health: Preparing Our Appeal, Advancing Our Catalysts, Continuing Our Mission
- OSR Holdings Inc. filed SEC Form 8-K: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, Regulation FD Disclosure, Financial Statements and Exhibits
- OSR Health Receives Nasdaq Staff Delisting Determination and Intends to Request Hearings Panel Appeal
- OSR Health Sees Global Shareholder Momentum at Critical Inflection Point
- SEC Form 10-Q filed by OSR Holdings Inc.